Magic usually involves smoke and mirrors, but the researchers filling the Four Seasons Hotel ballroom in Baltimore for Answer ALS’s “IgNight: Where the Magic of Collaboration Meets the Power of Science” on March 1 proved that the most impressive tricks involve data, cloud computing, artificial intelligence, and scientists who won’t take impossible for an answer….
Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked to elevated ALS risk. NEW ORLEANS, February 4, 2026 — Champion Insights officially commenced active research operations today in its nationwide study investigating why elite athletes, military veterans, and high-performance populations, like first responders, face disproportionately high rates — potentially up…
A digital holiday card of gratitude. Many thanks and Happy Holidays to all.
NEW ORLEANS, November 19, 2025: Alzheimer’s Disease Data Initiative (ADDI) has opened applications for the Global Neurodegeneration Proteomics Consortium (GNPC) Proteomics Data Challenge. Researchers worldwide are invited to analyze the GNPC Harmonized Data Set on the AD Workbench, including Answer ALS cohort datasets. The goal is to accelerate biomarker discovery and improve detection, prognosis, and…
All data from 1,100+ Answer ALS participants, including ALS TDI’s ARC study data, are now harmonized and accessible via the Neuromine Data Portal, forming the world’s largest open ALS research resource to accelerate discoveries. NEW ORLEANS, November 03, 2025 — Answer ALS today announced the full release of its comprehensive ALS clinical and multi-omics dataset,…
State-of-the-art remote-participation research seeks to understand how genetic factors linked to intense activities and lipid metabolism may increase ALS susceptibility NEW ORLEANS, August 13, 2025 — Answer ALS, in collaboration with ALS Therapy Development Institute (ALS TDI) and Augie’s Quest, today announced plans to launch Champion Insights, an ambitious research initiative designed to uncover critical…
NEW ORLEANS, July 22, 2025 — Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases. This effort, known as the Louisiana AI Drug Development Infrastructure for ALS (LADDIA), brings together leading institutions and innovators, including GATC Health — a…
Terri Thompson’s Multidisciplinary Approach Terri Thompson didn’t set out to work in ALS research. She had been working on a data-sharing platform for NASA, helping make research from spaceflight experiments easier for scientists to access and use. That experience opened the door to new collaborations, and eventually she was invited to join a group of…
Answer ALS is deeply alarmed and disappointed by Congress’ passage of the Full-Year Continuing Appropriations Act, which includes devastating cuts to ALS research funding. For years, funding for ALS research has grown steadily thanks to bipartisan support and the tireless efforts of the ALS community. These hard-fought increases have fueled groundbreaking progress in understanding ALS,…
Integrated data sharing platforms to accelerate research into ALS and Alzheimer’s disease by providing access to collaborative tools and datasets
Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally
The ALS Therapy Development Institute (ALS TDI), Answer ALS, and Microsoft are pleased to announce a collaboration that will bring together the two largest existing clinical and omics data sets relating to ALS. Through this partnership, comprehensive data collected through ALS TDI’s ALS Research Collaborative (ARC) will be added to Neuromine, an innovative data portal…
Data & TechnologyHarnessing Big Data with Advanced Analytics Neuromine is one of the world’s most robust and comprehensive ALS data resources, integrating multi-omics, clinical, and cellular datasets, while also linking to coordinating iPSC lines, biosamples, and other large-scale data platforms with analytic tools to maximize discovery and collaboration.
Multi-Omnics AnalysisComprehensive Biological Data Integration Making a comprehensive multi-omics datasets available that integrates genomics, transcriptomics, proteomics, epigenomics, and iPSC-derived motor neuron data that is freely accessible for analysis.
IPS Cells & Motor NeuronsGenerated 1,000 Participant-Derived Cell Lines Learn More about how to access 1,000 iPSC lines through our partners at the Cedars-Sinai Biomanufacturing Center
Clinic & enrollmentLeading Clinics Engaged to Complete Enrollment Enrollment in the Answer ALS program is complete, but you can Learn More about connected programs like Champion Insights, ALS Therapy Development’s ARC Program
